20th International AIDS Conference (AIDS 2014)

July 20-25, 2014; Melbourne, Australia
CCO is the official provider of online scientific analysis of AIDS 2014, through Capsule Summaries, downloadable slides, and expert faculty analysis of key studies on HIV treatment and prevention.

Highlights of AIDS 2014


Virologic failure was infrequent with both treatment strategies.

Released: July 29, 2014

Efficacy and tolerability appear comparable to that seen in HCV-monoinfected populations with no significant impact on control of HIV disease.

Released: July 22, 2014

Sofosbuvir plus ribavirin administered for 12 or 24 weeks depending on HCV genotype and treatment experience was associated with SVR12 rates of 84% to 89% in this coinfected population.

Released: July 23, 2014

This negative study of an NRTI-sparing strategy in patients with CCR5-tropic virus was closed early by the independent data and safety monitoring committee.

Released: July 24, 2014

Patients who maintained HIV-1 RNA < 50 copies/mL experienced no increase in virologic failure, whereas even transient increases > 200 copies/mL did increase risk.

Released: July 25, 2014

The findings were limited by the unknown contribution of adherence, unknown causes for antiretroviral switching, and unknown role of drug resistance in switching and/or subsequent virologic failure.

Released: July 24, 2014

No cases of virologic failure with dolutegravir in patients receiving NRTI-only background regimens, including among patients receiving NRTIs with reduced susceptibility.

Released: July 24, 2014

Race, high baseline HIV-1 RNA level, incomplete self-reported adherence, and low levels of genotypic resistance to NRTIs at baseline significantly predicted failure of NRTI-based second-line therapy by 96 weeks

Released: July 25, 2014

Persons at higher sexual risk were more likely to elect to take and adhere to PrEP

Released: July 25, 2014

In patients with normal BMI before starting ART, weight gain in the first year of ART was significantly associated with increased risk of cardiovascular disease.

Released: July 25, 2014
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?